MeCP2 dysfunction in Rett syndrome and related disorders

Current Opinion in Genetics and Development

Volumn 16, Issue 3, 2006, Pages 276-281

  Moretti, Paolo ^a   Zoghbi, Huda Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2;

AUTISM; BRAIN DISEASE; CHROMATIN STRUCTURE; CLINICAL FEATURE; GENE CONTROL; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LEARNING DISORDER; MENTAL DEFICIENCY; MENTAL DISEASE; METHYLATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RETT SYNDROME; REVIEW; RNA SPLICING; TRANSCRIPTION REGULATION; X CHROMOSOME LINKAGE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MUTATION; PHENOTYPE; RETT SYNDROME;

EID: 33646683567     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.04.009     Document Type: Review

References (50)

1. Hagberg B., Aicardi J., Dias K., and Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 14 (1983) 471-479
2. Rett A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien Med Wochenschr 116 (1966) 723-726
3. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., and Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23 (1999) 185-188
4. Percy A.K. Rett syndrome. Current status and new vistas. Neurol Clin 20 (2002) 1125-1141
5. Neul J.L., and Zoghbi H.Y. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 10 (2004) 118-128
6. Zoghbi H.Y. MeCP2 dysfunction in humans and mice. J Child Neurol 20 (2005) 736-740
7. Shahbazian M.D., and Zoghbi H.Y. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol 14 (2001) 171-176
8. Kriaucionis S., and Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res 32 (2004) 1818-1823. The authors describe the identification of a novel, alternatively spliced isoform of MeCP2. This isoform represents >90% of total MeCP2 in the brain.
9. ••].
10. Evans J.C., Archer H.L., Colley J.P., Ravn K., Nielsen J.B., Kerr A., Williams E., Christodoulou J., Gecz J., Jardine P.E., et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet 13 (2005) 1113-1120
11. Collins A.L., Levenson J.M., Vilaythong A.P., Richman R., Armstrong D.L., Noebels J.L., David Sweatt J., and Zoghbi H.Y. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 13 (2004) 2679-2689. Here, the authors demonstrate that approximately twofold overexpression of wild type MECP2 under its native promoter is detrimental and causes progressive neurological impairments in the mouse. They suggested that duplications or gain-of-function mutations in MECP2 might underlie human cases of X-linked neurobehavioral disorders.
12. •].
13. •].
14. •].
15. •] describe the clinical phenotype of individuals with MECP2 duplications.
16. Lewis J.D., Meehan R.R., Henzel W.J., Maurer-Fogy I., Jeppesen P., Klein F., and Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69 (1992) 905-914
17. Nan X., Meehan R.R., and Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 21 (1993) 4886-4892
18. Nan X., Tate P., Li E., and Bird A. DNA methylation specifies chromosomal localization of MeCP2. Mol Cell Biol 16 (1996) 414-421
19. Klose R.J., Sarraf S.A., Schmiedeberg L., McDermott S.M., Stancheva I., and Bird A.P. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19 (2005) 667-678. The authors report on the existence of high-affinity DNA-binding sites of MeCP2 and reveal that genomic sites occupied by MeCP2 and MBD2 (methyl-CpG binding domain 2) in vivo are mutually exclusive.
20. Nan X., Campoy F.J., and Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88 (1997) 471-481
21. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., and Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998) 386-389
22. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., and Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19 (1998) 187-191
23. Kaludov N.K., and Wolffe A.P. MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery. Nucleic Acids Res 28 (2000) 1921-1928
24. Kokura K., Kaul S.C., Wadhwa R., Nomura T., Khan M.M., Shinagawa T., Yasukawa T., Colmenares C., and Ishii S. The Ski protein family is required for MeCP2-mediated transcriptional repression. J Biol Chem 276 (2001) 34115-34121
25. Kimura H., and Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 278 (2003) 4806-4812
26. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., and Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278 (2003) 4035-4040
27. Klose R.J., and Bird A.P. MeCP2 behaves as an elongated monomer that does not stably associate with the Sin3a chromatin remodeling complex. J Biol Chem 279 (2004) 46490-46496. The authors demonstrate that MeCP2 purified from rat brain behaves as a monomeric protein with an elongated shape. Only a small fraction of MeCP2 interacts with Sin3a, and the interaction is not stable.
28. Jeffery L., and Nakielny S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J Biol Chem 279 (2004) 49479-49487
29. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci USA 102 (2005) 17551-17558. The authors demonstrate that MeCP2 interacts with the RNA-binding protein YB1 and regulates splicing of reporter minigenes. A mouse model of Rett syndrome demonstrated aberrant RNA splicing patterns.
30. Chen R.Z., Akbarian S., Tudor M., and Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27 (2001) 327-331
31. Guy J., Hendrich B., Holmes M., Martin J.E., and Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27 (2001) 322-326
32. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., Armstrong D., Paylor R., and Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35 (2002) 243-254
33. Moretti P., Bouwknecht J.A., Teague R., Paylor R., and Zoghbi H.Y. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet 14 (2005) 205-220
34. 308 mutant mice.
35. Matarazzo V., Cohen D., Palmer A.M., Simpson P.J., Khokhar B., Pan S.J., and Ronnett G.V. The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. Mol Cell Neurosci 27 (2004) 44-58
36. Asaka Y., Jugloff D.G., Zhang L., Eubanks J.H., and Fitzsimonds R.M. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis 21 (2006) 217-227. The authors describe synaptic plasticity deficits in the hippocampus of Mecp2 knockout mice.
37. Dani V.S., Chang Q., Maffei A., Turrigiano G.G., Jaenisch R., and Nelson S.B. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 102 (2005) 12560-12565. This study demonstrates reduced cortical activity in Mecp2 knockout mice.
38. Kishi N., and Macklis J.D. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 27 (2004) 306-321
39. Kerr A.M., Armstrong D.D., Prescott R.J., Doyle D., and Kearney D.L. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry 6 Suppl 1 (1997) 71-74
40. Zoghbi H.Y., Milstien S., Butler I.J., Smith E.O., Kaufman S., Glaze D.G., and Percy A.K. Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome. Ann Neurol 25 (1989) 56-60
41. Zoghbi H.Y., Percy A.K., Glaze D.G., Butler I.J., and Riccardi V.M. Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med 313 (1985) 921-924
42. Viemari J.C., Roux J.C., Tryba A.K., Saywell V., Burnet H., Pena F., Zanella S., Bevengut M., Barthelemy-Requin M., Herzing L.B., et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25 (2005) 11521-11530
43. Luikenhuis S., Giacometti E., Beard C.F., and Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA 101 (2004) 6033-6038. The authors show that expression of MeCP2 in post-mitotic neurons rescues the phenotypic abnormalities of Mecp2 knockout mice.
44. Tudor M., Akbarian S., Chen R.Z., and Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci USA 99 (2002) 15536-15541
45. Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., Jaenisch R., and Greenberg M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302 (2003) 885-889
46. Martinowich K., Hattori D., Wu H., Fouse S., He F., Hu Y., Fan G., and Sun Y.E. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302 (2003) 890-893
47. Samaco R.C., Hogart A., and LaSalle J.M. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 14 (2005) 483-492
48. Horike S., Cai S., Miyano M., Cheng J.F., and Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 37 (2005) 31-40. The authors describe disruption of a MeCP2-mediated chromatin looping structure at the Dlx5-Dlx6 locus in Mecp2 knockout mice and demonstrate that formation of a silent-chromatin loop is a mechanism underlying gene regulation by MeCP2.
49. Nuber U.A., Kriaucionis S., Roloff T.C., Guy J., Selfridge J., Steinhoff C., Schulz R., Lipkowitz B., Ropers H.H., Holmes M.C., et al. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol Genet 14 (2005) 2247-2256
50. Chang Q., Khare G., Dani V., Nelson S., and Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49 (2006) 341-348